{"id":"NCT00622869","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients","officialTitle":"A 24 Month, Multicenter, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2012-04","completion":"2012-04","firstPosted":"2008-02-25","resultsPosted":"2013-05-20","lastUpdate":"2013-05-27"},"enrollment":719,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Liver Transplantation"],"interventions":[{"type":"DRUG","name":"Tacrolimus (reduced tacrolimus)","otherNames":["FK-506","fujimycin","Prograf","Advagraf","Protopic"]},{"type":"DRUG","name":"Tacrolimus (tacrolimus elimination)","otherNames":["FK-506","fujimycin","Prograf","Advagraf","Protopic"]},{"type":"DRUG","name":"Tacrolimus (tacrolimus control)","otherNames":["FK-506","fujimycin","Prograf","Advagraf","Protopic"]},{"type":"DRUG","name":"Everolimus (reduced tacrolimus)","otherNames":["RAD-001","Zortress","Certican","Afinitor"]},{"type":"DRUG","name":"Everolimus (tacrolimus elimination)","otherNames":["RAD-001","Zortress","Certican","Afinitor"]},{"type":"DRUG","name":"Corticosteroids","otherNames":[]}],"arms":[{"label":"Everolimus + reduced tacrolimus","type":"EXPERIMENTAL"},{"label":"Tacrolimus elimination","type":"EXPERIMENTAL"},{"label":"Tacrolimus control","type":"ACTIVE_COMPARATOR"}],"summary":"This trial was designed to address important issues that impact recipients of liver allografts as well as clinicians, ie, renal function, reduction or discontinuation of tacrolimus early post-transplantation, and progression rate of fibrosis in hepatitis C virus (HCV) positive patients.","primaryOutcome":{"measure":"Incidence Rate of Composite Efficacy Failure From Randomization to Month 12","timeFrame":"Randomization to Month 12","effectByArm":[{"arm":"Everolimus + Reduced Tacrolimus","deltaMin":6.7,"sd":null},{"arm":"Tacrolimus Elimination","deltaMin":24.2,"sd":null},{"arm":"Tacrolimus Control Arm","deltaMin":9.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":91,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Colombia","Czechia","France","Germany","Hungary","Ireland","Israel","Italy","Netherlands","Russia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["28817434","26151607","23714399"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":138,"n":245},"commonTop":["Diarrhoea","Headache","Hypertension","Oedema peripheral","Pyrexia"]}}